Capital Research Global Investors Sells 140,097 Shares of Insulet Corporation $PODD

Capital Research Global Investors trimmed its holdings in Insulet Corporation (NASDAQ:PODD) by 3.1% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 4,408,972 shares of the medical instruments supplier’s stock after selling 140,097 shares during the period. Capital Research Global Investors owned about 6.27% of Insulet worth $1,253,224,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors have also recently made changes to their positions in PODD. Larson Financial Group LLC lifted its stake in shares of Insulet by 114.6% in the fourth quarter. Larson Financial Group LLC now owns 88 shares of the medical instruments supplier’s stock valued at $25,000 after buying an additional 47 shares in the last quarter. Elyxium Wealth LLC bought a new position in shares of Insulet in the fourth quarter valued at $28,000. Fideuram Asset Management Ireland dac bought a new position in shares of Insulet in the fourth quarter valued at $41,000. Measured Wealth Private Client Group LLC bought a new position in shares of Insulet in the third quarter valued at $49,000. Finally, Osterweis Capital Management Inc. bought a new position in shares of Insulet in the second quarter valued at $51,000.

Insider Transactions at Insulet

In related news, Director Timothy C. Stonesifer acquired 2,790 shares of the firm’s stock in a transaction that occurred on Wednesday, June 3rd. The stock was acquired at an average price of $143.51 per share, for a total transaction of $400,392.90. Following the completion of the acquisition, the director owned 9,041 shares of the company’s stock, valued at approximately $1,297,473.91. This represents a 44.63% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 0.36% of the company’s stock.

Insulet Stock Performance

Shares of PODD stock opened at $153.22 on Friday. The firm has a 50-day moving average of $175.73 and a 200-day moving average of $238.90. The company has a market cap of $10.61 billion, a P/E ratio of 35.63, a P/E/G ratio of 1.21 and a beta of 1.13. The company has a debt-to-equity ratio of 0.71, a current ratio of 2.49 and a quick ratio of 1.81. Insulet Corporation has a one year low of $140.63 and a one year high of $354.88.

Insulet (NASDAQ:PODD) last announced its earnings results on Wednesday, May 6th. The medical instruments supplier reported $1.42 EPS for the quarter, beating the consensus estimate of $1.19 by $0.23. The company had revenue of $761.70 million during the quarter, compared to the consensus estimate of $729.89 million. Insulet had a net margin of 10.44% and a return on equity of 26.87%. The firm’s revenue for the quarter was up 33.9% on a year-over-year basis. During the same quarter in the prior year, the company posted $1.02 earnings per share. Insulet has set its FY 2026 guidance at 6.210- EPS. Equities research analysts forecast that Insulet Corporation will post 6.46 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of research analysts have weighed in on PODD shares. Rothschild & Co Redburn reaffirmed a “neutral” rating and issued a $220.00 price objective (down from $380.00) on shares of Insulet in a research note on Friday, April 24th. Royal Bank Of Canada reaffirmed an “outperform” rating and issued a $280.00 price objective on shares of Insulet in a research note on Wednesday, May 27th. Canaccord Genuity Group dropped their price objective on shares of Insulet from $435.00 to $249.00 and set a “buy” rating on the stock in a research note on Thursday, May 7th. Benchmark reiterated a “buy” rating on shares of Insulet in a report on Wednesday, May 27th. Finally, Citigroup lowered their target price on shares of Insulet from $175.00 to $165.00 and set a “neutral” rating for the company in a report on Thursday, May 28th. Twenty-one equities research analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $252.04.

About Insulet

Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company’s core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet’s products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.

The company’s product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.